However, given the heterogeneity in EpCAM expression for patients with castration-resistant prostate cancer (Figure 9B), the use of EpCAM as a sole biomarker for CTC detection poses some concerns about the detection of PCa cells that express little to no epithelial markers following EMT. This evidence concerns the gene EPCAM and posterior cortical atrophy.